Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor for Lenalidomide-Refractory Multiple Myeloma
NCT04519476Phase 1Recruiting
- Sponsor
- ONCOtherapeutics
- Start
- Nov 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selinexor in multiple myeloma (MM), sponsored by ONCOtherapeutics. Primary endpoints: Overall Response at 30 months and Clinical Benefit Rate at 30 months. Started Nov 2020; status: recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04519476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04519476.